Chris MacDonald

Chris MacDonald

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

CGC Stock Alert: 7 Things to Know About the Latest Canopy Growth Deal

Today, investors in Canopy Growth and CGC stock are buying into this cannabis player heavily as the company announced a key acquisition.

OCGN Stock: One Big Reason Why Ocugen Is Climbing Today

Covid-19 vaccine play Ocugen is seeing impressive investor interest today, with OCGN stock seeing double-digit gains at the time of writing.

#AMCSqueeze: What Is Going on With AMC Stock Today?

Recent news that a short seller has exited their position in AMC stock has made AMC go viral on social media platforms today.

GRVI Stock Is Soaring Thanks to This Amazon-Sized Catalyst

Today, Grove's announcement move to launch a brand targeted at growing the company's e-commerce business has GRVI stock surging.

ORPH Stock Alert: What’s Going on With Red-Hot Orphazyme Today?

Today, retail investors and traders appear willing to put some big money down on Orphazyme and ORPH stock as a potential short-squeeze play.